Lexicon Pharmaceuticals, Inc. (Lexicon Pharmaceuticals) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon Pharmaceuticals uses its gene knockout technologies and an integrated platform of medical technologies to study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. It has five drug programs in various stages of clinical development and has advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research. Its drug program includes LX4211, LX1032, LX1033, LX2931 and LX7101.